Exploring cognitive and biological correlates of sleep quality and their potential links with Alzheimer’s disease (ALFASleep project): protocol for an observational study

Autor: Henrik Zetterberg, Kaj Blennow, José Luis Molinuevo, Andreea Radoi, Carolina Minguillón, Karine Fauria, Carme Deulofeu, Marc Suárez-Calvet, Oriol Grau-Rivera, Alex Iranzo, Iva Knezevic, Núria Tort-Colet, Laura Stankeviciute, Laura Hernández, Sherezade Fuentes-Julián, Israel Turull, David Fusté, Gonzalo Sánchez-Benavides, Eider M Arenaza-Urquijo, Sebastian C Holst, Pilar Garcés, Thomas Mueggler, Aurora Arqueros, Juan Domingo Gispert
Jazyk: angličtina
Rok vydání: 2022
Předmět:
Zdroj: BMJ Open, Vol 12, Iss 12 (2022)
Druh dokumentu: article
ISSN: 2044-6055
35420871
DOI: 10.1136/bmjopen-2022-067159
Popis: Introduction The growing worldwide prevalence of Alzheimer’s disease (AD) and the lack of effective treatments pose a dire medical challenge. Sleep disruption is also prevalent in the ageing population and is increasingly recognised as a risk factor and an early sign of AD. The ALFASleep project aims to characterise sleep with subjective and objective measurements in cognitively unimpaired middle/late middle-aged adults at increased risk of AD who are phenotyped with fluid and neuroimaging AD biomarkers. This will contribute to a better understanding of the pathophysiological mechanisms linking sleep with AD, thereby paving the way for the development of non-invasive biomarkers and preventive strategies targeting sleep.Methods and analysis We will invite 200 participants enrolled in the ALFA+ (for ALzheimer and FAmilies) prospective observational study to join the ALFASleep study. ALFA+ participants are cognitively unimpaired middle-aged/late middle-aged adults who are followed up every 3 years with a comprehensive set of evaluations including neuropsychological tests, blood and cerebrospinal fluid (CSF) sampling, and MRI and positron emission tomography acquisition. ALFASleep participants will be additionally characterised with actigraphy and CSF–orexin-A measurements, and a subset (n=90) will undergo overnight polysomnography. We will test associations of sleep measurements and CSF–orexin-A with fluid biomarkers of AD and glial activation, neuroimaging outcomes and cognitive performance. In case we found any associations, we will test whether changes in AD and/or glial activation markers mediate the association between sleep and neuroimaging or cognitive outcomes and whether sleep mediates associations between CSF–orexin-A and AD biomarkers.Ethics and dissemination The ALFASleep study protocol has been approved by the independent Ethics Committee Parc de Salut Mar, Barcelona (2018/8207/I). All participants have signed a written informed consent before their inclusion (approved by the same ethics committee). Study findings will be presented at national and international conferences and submitted for publication in peer-reviewed journals.Trial registration number NCT04932473.
Databáze: Directory of Open Access Journals
Externí odkaz: